BRAF and neoplasm: Here, we present the results of cohort 2 by assessing (I) the percentage of patients with RAS, BRAF and EGFR mutations and (II) the concordance rate for RAS mutational status in tumor-tissue and plasma samples (using the IdyllaTM) at baseline in RAS wild-type mCRC patients starting their standard first-line treatment.